Does Tigecycline Cause Liver Enzyme Elevations?
Tigecycline, a glycylcycline antibiotic, links to increased liver enzymes (ALT, AST) in clinical data, with incidence rising at higher doses. In phase 3 trials, 400 mg loading dose followed by 100 mg twice daily showed ALT elevations >3x upper limit of normal (ULN) in 15-25% of patients versus 10-15% on 50 mg twice daily.[1][2] Standard dose is 50 mg IV every 12 hours after 100 mg load; higher doses (up to 200 mg/day) amplify hepatotoxicity risk, per FDA label warnings for dose-dependent transaminase rises.[3]
What Clinical Trials Show on Dose and Liver Effects?
Pooled safety data from 1,327 tigecycline patients (mostly 50 mg BID) reported abnormal ALT in 13.5% and AST in 11.5%, versus 9.4% and 8.6% on comparators. Elevated doses in exploratory trials (100 mg BID) doubled rates to ~26% for ALT >3x ULN, often reversible post-treatment. Severe cases (>10x ULN) occurred in <1%, more frequent at high doses.[1][4] No direct causation proven, but dose-response pattern holds across respiratory, skin, and intra-abdominal infection studies.
How Does This Compare to Other Antibiotics?
Tigecycline's hepatotoxicity exceeds comparators like vancomycin (ALT ~5-10%) or levofloxacin (~8%), with odds ratio 1.6-2.0 for elevations at standard doses, higher at 100 mg BID.[2][5] Carbapenems show similar low rates (~10%), but tigecycline's biliary excretion may concentrate it in liver, explaining dose sensitivity.
When Do Liver Enzyme Increases Happen?
Onset typically within 7-14 days of starting therapy, peaking mid-course, resolving 1-4 weeks after stopping. Risk factors include pre-existing liver disease, longer duration (>14 days), and doses >100 mg/day. Monitor LFTs weekly; discontinue if >5x ULN with symptoms.[3]
Who Is at Higher Risk from High-Dose Tigecycline?
Patients with Child-Pugh B/C cirrhosis face 2-3x higher ALT/AST spikes; avoid high doses. Obesity, diabetes, or concurrent hepatotoxins (e.g., acetaminophen) compound effects. Post-marketing reports note rare fulminant hepatitis at escalated doses for MDR infections.[3][6]
Regulatory Warnings and Guidelines
FDA black-boxes tigecycline for increased mortality risk, but labels specify dose-related LFT abnormalities. IDSA guidelines recommend standard 50 mg BID for most; reserve higher investigational doses for salvage, with close monitoring. EMA echoes dose-dependent hepatotoxicity.[3][7]
Sources
[1] Tigecycline package insert (FDA)
[2] Clinical trial meta-analysis, J Antimicrob Chemother (2010)
[3] FDA Tygacil label updates
[4] Pooled phase 3 data, Clin Infect Dis (2005)
[5] Hepatotoxicity review, Expert Opin Drug Saf (2013)
[6] Post-marketing surveillance, Pharmacoepidemiol Drug Saf (2015)
[7] IDSA guidelines on tigecycline use